Orphan Drug Exclusivity: The Strategy That Cuts Both Ways

← Back to All Insights

The Orphan Drug Act of 1983 gives developers of drugs for rare diseases several incentives: a tax credit for qualified clinical testing costs (25% since 2018, after the Tax Cuts and Jobs Act halved the original 50%), an exemption from the FDA application fee for orphan-designated applications that do not include a non-rare indication, and seven years of marketing exclusivity after approval. Rare disease drugs are now a large share of new approvals: of the 46 novel drugs FDA's Center for Drug Evaluation and Research approved in 2025, 25 had orphan designation. The strategy works, but it carries constraints that diligence should read carefully.

Orphan designation shapes a sponsor's clinical, commercial and pricing path, and some of its effects surface only years into commercialization.

What Orphan Exclusivity Blocks

For seven years after approval, FDA may not approve another application for the same drug for the same approved use or indication within the rare disease, except in limited circumstances such as the exclusivity holder's consent or its inability to supply enough of the drug. For comparison, a new chemical entity receives five years of exclusivity and a biologic reference product twelve. Orphan exclusivity does not block a different drug for the same disease, and it does not block the same drug for a different use.

The scope of that protection was contested. After the Eleventh Circuit's 2021 decision in Catalyst Pharmaceuticals v. Becerra read exclusivity as covering the whole disease or condition, FDA said in January 2023 that it would keep tying exclusivity to approved uses or indications for other drugs. In February 2026, the Consolidated Appropriations Act, 2026 amended the statute to say so expressly: exclusivity covers the same approved use or indication within the rare disease. For diligence, that means an exclusivity period protects the labeled indication, not every patient with the disease.

Designation Strategy and Narrow Indications

Sponsors sometimes define a narrow population in order to qualify for orphan designation. FDA has limited this in specific cases: under its December 2017 guidance, it no longer grants orphan designation for a pediatric subpopulation of a common disease, one affecting 200,000 or more people overall. Investors should examine whether a target's orphan strategy reflects real differences in disease biology or a definitional carve-out, and how much of the commercial plan depends on it.

Pricing and Payer Scrutiny

Orphan drugs can command high prices because treated populations are small and alternatives are few, and that pricing draws payer attention, including prior authorization and outcomes-based contracting. The payer path for an orphan drug deserves the same diligence as its regulatory path.

Orphan Status and Medicare Negotiation

The Inflation Reduction Act originally excluded from Medicare price negotiation only drugs with a single orphan designation approved solely for that condition. The 2025 reconciliation law, signed July 4, 2025, broadened the exclusion to drugs designated for one or more rare diseases and approved only for those conditions, and the eligibility clock now starts only when a drug is approved for a non-orphan indication. That leaves a strategic tension: a non-orphan indication can grow revenue but can also start the negotiation clock. See our article on Medicare drug price negotiation.

Diligence Questions for Orphan-Focused Therapeutics

Does the orphan designation rest on disease biology or on a definitional carve-out? What does the approved indication actually cover, now that exclusivity follows the approved use or indication? How large is the addressable population at realistic penetration? What happens if a competitor gains approval of the same drug for a different use in the same disease, or of a different drug for the same use? Is the sponsor pursuing non-orphan indications, and how does that interact with Medicare negotiation? What does coverage look like across major commercial plans and Medicare?

When Orphan Strategy Stops Working

Orphan strategies can weaken when the same molecule is approved for a larger non-orphan indication, when competitors enter adjacent indications and fragment the prescriber base, when payers tighten coverage across rare disease therapies, or when the commercial organization grows beyond what small-population economics support. Models that treat orphan economics as linear can miss these inflection points.

Orphan drug strategy is one of the most effective regulatory and commercial pathways available when the underlying disease biology supports it, and a fragile one when it does not. Diligence should test not only whether orphan designation is achievable, but whether the resulting commercial structure, including pricing, payer dynamics and life-cycle constraints, supports a viable business.